TKNO
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E N/A, Graham Number None
- P/B ratio of 2.27 is relatively moderate for the sector
- Negative earnings make P/E and Graham Number inapplicable
- Price/Sales of 3.85 is high for a non-profitable company
Ref Growth rates
- Revenue growth is positive (7.8%)
- EPS is trending upward YoY (+18.2%)
- Forward P/E remains negative (-7.46)
- Growth is modest compared to sector averages
Ref Historical trends
- Recent 1-month slight recovery (+4.3%)
- Catastrophic 5-year return (-88.4%)
- Heavy 1-year decline (-49.6%)
Ref Piotroski F-Score
- Excellent Current Ratio (4.58)
- Low Debt/Equity (0.41)
- Piotroski F-Score of 1/9 indicates severe fundamental weakness
Ref Yield, Payout
- No dividend payments
- 0/100 Dividend Strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TKNO and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TKNO
Alpha Teknova, Inc.
Primary
|
-88.4% | +41.3% | -49.6% | -49.4% | +4.3% | -3.6% |
|
RCEL
AVITA Medical, Inc.
Peer
|
-74.5% | -65.7% | -44.2% | +28.8% | +22.7% | +2.6% |
|
TLSA
Tiziana Life Sciences Ltd
Peer
|
-51.0% | +16.4% | +7.1% | -38.3% | 0.0% | +5.2% |
|
SPRO
Spero Therapeutics, Inc.
Peer
|
-77.5% | +57.1% | +264.7% | +24.4% | +11.8% | +3.0% |
|
HRTX
Heron Therapeutics, Inc.
Peer
|
-94.8% | -68.8% | -53.1% | -33.4% | -12.1% | +6.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TKNO
Alpha Teknova, Inc.
|
BEARISH | $155.94M | - | -22.8% | -42.6% | $2.91 | |
|
RCEL
AVITA Medical, Inc.
|
BEARISH | $157.45M | - | -% | -67.8% | $5.14 | Compare |
|
TLSA
Tiziana Life Sciences Ltd
|
BEARISH | $153.97M | - | -232.3% | -% | $1.21 | Compare |
|
SPRO
Spero Therapeutics, Inc.
|
BEARISH | $159.2M | 18.33 | 16.3% | 12.8% | $2.75 | Compare |
|
HRTX
Heron Therapeutics, Inc.
|
BEARISH | $160.82M | - | -% | -13.0% | $0.85 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-06 | LOWELL MATTHEW | Chief Financial Officer | Purchase | 40,000 | $87,616 |
| 2026-03-06 | GUNSTREAM STEPHEN | Chief Executive Officer | Purchase | 26,000 | $55,801 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Past News Coverage
Recent headlines mentioning TKNO from our newsroom.